These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11229704)

  • 21. AERS spider: an online interactive tool to mine statistical associations in Adverse Event Reporting System.
    Grigoriev I; zu Castell W; Tsvetkov P; Antonov AV
    Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):795-801. PubMed ID: 24677538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Excess Ticagrelor Mortality in the Food and Drug Administration Adverse Event Reporting System: Time to Recount PLATO Trial Deaths.
    Serebruany VL; Fortmann SD; Cherepanov V; Litvinov O; Kim MH; Marciniak TA
    Am J Med; 2017 Jun; 130(6):e245-e246. PubMed ID: 28161342
    [No Abstract]   [Full Text] [Related]  

  • 23. IOM panel mulls over adverse-event reporting.
    Young D
    Am J Health Syst Pharm; 2005 Dec; 62(24):2590-1. PubMed ID: 16333055
    [No Abstract]   [Full Text] [Related]  

  • 24. New FDA initiatives.
    Somberg JC
    J Clin Pharmacol; 1993 Jul; 33(7):587. PubMed ID: 8366185
    [No Abstract]   [Full Text] [Related]  

  • 25. The FDA Sentinel Initiative - An Evolving National Resource.
    Platt R; Brown JS; Robb M; McClellan M; Ball R; Nguyen MD; Sherman RE
    N Engl J Med; 2018 Nov; 379(22):2091-2093. PubMed ID: 30485777
    [No Abstract]   [Full Text] [Related]  

  • 26. Physicians' liability for adverse drug reactions.
    Kaufman MB; Stoukides CA; Campbell NA
    South Med J; 1994 Aug; 87(8):780-4. PubMed ID: 8052883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Report slams US FDA's drug safety reform efforts.
    Bristol N
    Lancet; 2007 Mar; 369(9567):1072. PubMed ID: 17405202
    [No Abstract]   [Full Text] [Related]  

  • 28. Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems.
    Gosho M; Maruo K; Tada K; Hirakawa A
    Eur J Clin Pharmacol; 2017 Jun; 73(6):779-786. PubMed ID: 28280890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of newly approved drugs: implications for prescribing.
    Temple RJ; Himmel MH
    JAMA; 2002 May; 287(17):2273-5. PubMed ID: 11980528
    [No Abstract]   [Full Text] [Related]  

  • 30. Monitoring adverse drug reactions across a nationwide health care system using information technology.
    Emmendorfer T; Glassman PA; Moore V; Leadholm TC; Good CB; Cunningham F
    Am J Health Syst Pharm; 2012 Feb; 69(4):321-8. PubMed ID: 22302257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety concerns at the FDA.
    Lancet; 2005 Feb 26-Mar 4; 365(9461):727-8. PubMed ID: 15733696
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug product characteristics that foster drug-use-system errors.
    Cohen MR
    Am J Health Syst Pharm; 1995 Feb; 52(4):395-9. PubMed ID: 7757867
    [No Abstract]   [Full Text] [Related]  

  • 33. Processing and evaluation of adverse drug experience reports at the Food and Drug Administration Center for Veterinary Medicine.
    Keller WC; Bataller N; Oeller DS
    J Am Vet Med Assoc; 1998 Jul; 213(2):208-11. PubMed ID: 9676589
    [No Abstract]   [Full Text] [Related]  

  • 34. Assessing drug safety and consequences of drug withdrawals.
    Mamdani M
    J Am Pharm Assoc (2003); 2004; 44(6):659-60. PubMed ID: 15637847
    [No Abstract]   [Full Text] [Related]  

  • 35. USP says thousands of drug names look or sound alike.
    Thompson CA
    Am J Health Syst Pharm; 2008 Mar; 65(5):386-8. PubMed ID: 18281728
    [No Abstract]   [Full Text] [Related]  

  • 36. The missing voice of patients in drug-safety reporting.
    Basch E
    N Engl J Med; 2010 Mar; 362(10):865-9. PubMed ID: 20220181
    [No Abstract]   [Full Text] [Related]  

  • 37. 150 years of pharmacovigilance.
    Routledge P
    Lancet; 1998 Apr; 351(9110):1200-1. PubMed ID: 9643710
    [No Abstract]   [Full Text] [Related]  

  • 38. The role of litigation in defining drug risks.
    Kesselheim AS; Avorn J
    JAMA; 2007 Jan; 297(3):308-11. PubMed ID: 17227983
    [No Abstract]   [Full Text] [Related]  

  • 39. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Semantic categories and relations for modelling adverse drug reactions towards a categorial structure for pharmacovigilance.
    Bousquet C; Trombert B; Kumar A; Rodrigues JM
    AMIA Annu Symp Proc; 2008 Nov; 2008():61-5. PubMed ID: 18998982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.